

<https://helda.helsinki.fi>

---

## Childhood-onset Leber hereditary optic neuropathy

Majander, Anna

2017-11

---

Majander , A , Bowman , R , Poulton , J , Antcliff , R J , Reddy , M A , Michaelides , M , Webster , A R , Chinnery , P F , Votruba , M , Moore , A T & Yu-Wai-Man , P 2017 , ' Childhood-onset Leber hereditary optic neuropathy ' , British Journal of Ophthalmology , vol. 101 , no. 11 , pp. 1505-1509 . <https://doi.org/10.1136/bjophthalmol-2016-310072>

---

<http://hdl.handle.net/10138/232822>

<https://doi.org/10.1136/bjophthalmol-2016-310072>

---

cc\_by

publishedVersion

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*

# Childhood-onset Leber hereditary optic neuropathy

Anna Majander,<sup>1,2,3</sup> Richard Bowman,<sup>4</sup> Joanna Poulton,<sup>5</sup> Richard J Antcliff,<sup>6</sup>  
M Ashwin Reddy,<sup>2</sup> Michel Michaelides,<sup>1,2</sup> Andrew R Webster,<sup>1,2</sup> Patrick F Chinnery,<sup>7,8,9</sup>  
Marcela Votruba,<sup>10</sup> Anthony T Moore,<sup>1,2,11</sup> Patrick Yu-Wai-Man<sup>1,2,7,12</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bjophthalmol-2016-310072>).

For numbered affiliations see end of article.

## Correspondence to

Dr Anna Majander, UCL Institute of Ophthalmology and Moorfields Eye Hospital, 162 City Road, London, EC1V 2PD London, UK; and Department of Ophthalmology, Helsinki University Hospital, and University of Helsinki, P.O. Box 220, Helsinki FI-00029, Finland; [anna.majander@hus.fi](mailto:anna.majander@hus.fi)

Received 15 December 2016  
Revised 20 February 2017  
Accepted 23 February 2017  
Published Online First  
17 March 2017

## ABSTRACT

**Background** The onset of Leber hereditary optic neuropathy (LHON) is relatively rare in childhood. This study describes the clinical and molecular genetic features observed in this specific LHON subgroup.

**Methods** Our retrospective study consisted of a UK paediatric LHON cohort of 27 patients and 69 additional cases identified from a systematic review of the literature. Patients were included if visual loss occurred at the age of 12 years or younger with a confirmed pathogenic mitochondrial DNA mutation: m.3460G>A, m.11778G>A or m.14484T>C.

**Results** In the UK paediatric LHON cohort, three patterns of visual loss and progression were observed: (1) classical acute (17/27, 63%); (2) slowly progressive (4/27, 15%); and (3) insidious or subclinical (6/27, 22%). Diagnostic delays of 3–15 years occurred in children with an insidious mode of onset. Spontaneous visual recovery was more common in patients carrying the m.3460G>A and m.14484T>C mutations compared with the m.11778G>A mutation. Based a meta-analysis of 67 patients with available visual acuity data, 26 (39%) patients achieved a final best-corrected visual acuity (BCVA)  $\geq 0.5$  Snellen decimal in at least one eye, whereas 13 (19%) patients had a final BCVA  $< 0.05$  in their better seeing eye.

**Conclusions** Although childhood-onset LHON carries a relatively better visual prognosis, approximately 1 in 5 patients will remain within the visual acuity criteria for legal blindness in the UK. The clinical presentation can be insidious and LHON should be considered in the differential diagnosis when faced with a child with unexplained subnormal vision and optic disc pallor.

## INTRODUCTION

Leber hereditary optic neuropathy (LHON) (OMIM 535000) is a mitochondrial disorder that classically presents with acute or subacute bilateral loss of central vision in young adult men.<sup>1–3</sup> About 90% of patients carry one of the three major disease-causing LHON mitochondrial DNA (mtDNA) mutations (*MTND1*m.3460G>A, *MTND4*m.11778G>A and *MTND6*m.14484T>C), all of which encode for critical complex I subunits of the mitochondrial respiratory chain.<sup>4</sup> The greater availability of molecular genetic testing has broadened the phenotypical spectrum associated with LHON to include patients with more slowly progressive visual deterioration exceeding 6 months in duration, and those with an insidious/subclinical course characterised by the incidental discovery of subnormal vision and optic atrophy in the absence of overt visual symptoms.<sup>1–5</sup> Although disease conversion can occur anywhere from the first to the eighth decade of life, the peak age of onset of

visual loss among LHON carriers is 20–30 years old.<sup>1–4</sup> Childhood-onset disease is relatively rare and less than 10% of patients were 12 years old or younger at the time of diagnosis in previously published case series.<sup>1–6–10</sup> Although there are limited data on this important patient subgroup, the phenotype seems distinct from classical adult-onset LHON with atypical patterns of vision loss and a better visual prognosis as reported in a previously published study of 18 patients with childhood-onset LHON.<sup>7</sup>

The aim of our study was to describe the clinical and molecular genetic characteristics associated with childhood-onset LHON, in particular the disease course and visual prognosis to better inform genetic counselling. We retrieved data for all eligible patients with LHON that were seen at three major diagnostic centres for inherited optic neuropathies in the UK. This UK paediatric LHON cohort was then combined with additional cases identified from a systematic review of the literature to generate a comprehensive meta-analysis of childhood LHON.

## PATIENTS AND METHODS

### Study population

This is a retrospective observational study approved by the local ethics committee at Moorfields Eye Hospital and it conformed to the standards set by the Declaration of Helsinki. Patients with LHON with disease onset at the age of 12 years or younger were identified from the clinical and genetic databases of the three main national diagnostic centres for inherited optic neuropathies in the UK (London, Oxford and Newcastle upon Tyne). We only included patients who carried one of the three canonical pathogenic mtDNA mutations, that is, m.3460G>A, m.11778G>A and m.14484T>C. Additional clinical information where relevant was sought from the original referring clinicians. Best-corrected visual acuities (BCVAs) at disease onset, at the nadir and at the last follow-up clinic visit were recorded. Patients were subclassified into three groups based on the mode of onset and progression of vision loss: (1) *acute*, if visual acuity deteriorated rapidly reaching the nadir within 6 months from disease onset; (2) *slowly progressive*, if visual deterioration occurred over a period exceeding 6 months; and (3) *insidious* or *subclinical*, if the patient was clinically asymptomatic at the time that a diagnosis of optic atrophy or subnormal vision was made, and there was no change in visual acuity during subsequent follow-ups.<sup>1–7</sup> Spontaneous visual recovery was defined as an improvement of BCVA by two lines or more on the ETDRS chart or from off-chart to on-chart visual acuity (0.05



CrossMark

**To cite:** Majander A, Bowman R, Poulton J, et al. *Br J Ophthalmol* 2017;**101**:1505–1509.

Snellen decimal (SD)). A binocular visual acuity of at least 0.5 (6/12) is the minimum standard for driving in the UK (<https://www.gov.uk/driving-eyesight-rules>, accessed on 8 November 2016) and below 0.05 (3/60) is the legal definition of registrable blindness in the UK (<https://www.gov.uk/government/publications/guidance-published-on-registering-a-vision-impairment-as-a-disability>, accessed on 8 November 2016).

When available, spectral-domain optical coherence tomography (SD-OCT) data were retrieved from the database of the Spectralis (Heidelberg Engineering, Heidelberg, Germany) and Cirrus HD-OCT 4000 (Carl Zeiss Meditec, Dublin, California, USA) platforms, and compared with the normative data described elsewhere.<sup>11 12</sup>

### Systematic literature review

A comprehensive literature search was conducted using the search terms 'LHON', 'Leber hereditary optic neuropathy' or 'Leber's hereditary optic neuropathy' and 'child', 'childhood', 'paediatric' or 'paediatric' on PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>, accessed on 8 November 2016). We also reviewed all the papers that included previously published publications on childhood LHON in their reference lists. A patient with LHON was included in our meta-analysis only if there was confirmation of the m.3460G>A, m.11778G>A or m.14484T>C mtDNA mutation, and disease onset was clearly stated as being before the age of 12 years or younger. None of the patients included in the historical case series was present in the UK paediatric LHON cohort. Due to the retrospective nature of our systematic literature review, more detailed clinical information regarding visual acuity and disease progression was not available for 29 of the 69 eligible patients included in our historical case series.

### Statistical analysis

The Kruskal-Wallis test and Mann-Whitney U independent samples test were used for comparing the age at onset between the LHON genotypes and the distribution of retinal layer thickness in LHON and control eyes, respectively. The Spearman's rank correlation test was used to assess for the strength of dependence between BCVA and retinal layer thickness (IBM Statistical Package of Social Sciences (SPSS) 22 V.100).

## RESULTS

### UK paediatric LHON cohort

The UK paediatric LHON cohort included 27 patients who were 2–11 years old (mean=6.9 years, SD=2.9 years) at the time of onset of visual loss or when subnormal visual acuity or optic disc pallor first became apparent (table 1). Thirteen patients (48%) carried the m.11778G>A mutation, seven patients (26%) the m.3460G>A mutation and seven patients (26%) the m.14484T>C mutation (table 2). Patients 24–27 belonged to the same family and out of five affected family members, four of them developed visual loss before the age of 6 years. There was a known family history of LHON in 19 probands (70%). The male:female ratio varied between 2.5 and 3.3 for the three primary LHON mtDNA mutations with an overall male:female ratio of 3.0. There was no statistically significant difference in the age of disease onset between the LHON genotypes (Kruskal-Wallis test,  $p=0.831$ ).

The majority of patients (17/27, 63%) experienced acute or subacute visual loss with the nadir being reached within 6 months of first disease onset. This mode of presentation was the most common in children harbouring the m.3460G>A mutation (6/7, 86%). In four patients (15%), visual acuity deteriorated slowly over a period extending up to 2 years. Three patients in this subgroup carried the m.14484T>C mutation

and one the m.11778G>A mutation. There was an unexpectedly large number of children (6/27, 22%) with insidious or subclinical vision loss in the UK paediatric LHON cohort. Subnormal vision or optic disc pallor were detected during the first 2 years of life ( $n=4$ ) or after failing the preschool visual screening assessment ( $n=2$ ), which is mandatory in the UK for all 4–5-year-olds (table 1). None of these children demonstrated or were suspected of having impaired visual performance during their early years and no visual deterioration occurred on subsequent follow-up. Molecular genetic confirmation of LHON in this insidious/subclinical group was markedly delayed between 3 years and 15 years due to the atypical presentation.

The mean final BCVA in the whole group of patients with childhood-onset LHON was 0.39 SD (SD=0.38, range=light perception–1.2 SD, median=0.25) with a mean disease duration of 18 years (SD=16 years, range=1–56 years, median=16 years). BCVA was  $\geq 0.5$  in 20/54 (37%) eyes and 14/27 (52%) patients had at least 1 eye with BCVA  $\geq 0.5$ . Conversely, BCVA was  $<0.05$  in 11/54 (20%) eyes and 5/27 (19%) patients met the legal definition of blindness with a BCVA  $<0.05$  in their better seeing eye. The m.11778G>A mutation was associated with a worse visual outcome compared with the m.3460G>A and m.14484T>C mutations (table 2 and figure 1). Ten (37%) patients had asymmetrical final BCVA with a difference  $\geq 2$  lines on the ETDRS chart, and this was associated with: (1) asymmetrical visual loss in the acute stage ( $n=2$ ); (2) asymmetrical visual recovery following an acute disease onset ( $n=2$ ); (3) slowly progressive visual loss ( $n=3$ ); and (4) an insidious/subclinical course ( $n=3$ ). Patient 26, who harboured the m.14484T>C mutation, presented with slowly progressive visual deterioration in only one eye. In patients presenting with acute LHON, spontaneous visual recovery occurred in 20/34 (59%) eyes and 16 (80%) of the recovered eyes achieved a BCVA  $\geq 0.5$ . The mean time to recovery was 29 months (SD=18 months, range=9–60 months) and there were no significant differences between mutation subgroups (m.3460G>A, mean=28 months; m.11778G>A, mean=27 months; m.14484T>C, mean=32 months; Kruskal-Wallis test,  $p=0.958$ ). Visual outcome was bimodal in the acute LHON group with a BCVA  $\geq 0.5$  in 17/34 (50%) eyes and  $<0.05$  in 10/34 (29%) eyes (figure 2). The majority of eyes for patients classified as having slowly progressive (5/8, 63%) or insidious/subclinical (11/12, 82%) LHON had BCVA  $<0.5$ .

SD-OCT imaging of the optic nerve head was available for 26 eyes of 13 patients. There was a significant reduction in the average peripapillary retinal nerve fibre layer (RNFL) thickness ranging from 49.0% to 58.4% compared with control values. On subgroup analysis, there was no significant correlation between BCVA and peripapillary RNFL thickness in any of the individual quadrants (data not shown). Perifoveal volumetric retinal SD-OCT scans were available for 10 eyes of five patients. Retinal thickness was significantly reduced in the LHON group (mean  $\pm$  SD=295.5  $\pm$  17.7  $\mu$ m) compared with normal controls (mean  $\pm$  SD=340.8  $\pm$  13.3  $\mu$ m, Mann-Whitney U test,  $p<0.001$ ). This was specifically due to marked thinning of the ganglion cell layer-inner plexiform layer (GCL-IPL) complex in the LHON group (mean  $\pm$  SD=43.2  $\pm$  2.9  $\mu$ m) compared with normal controls (mean  $\pm$  SD=93.5  $\pm$  7.8  $\mu$ m, Mann-Whitney U test,  $p<0.001$ ). There was a statistically significant correlation between BCVA and the remaining GCL-IPL thickness (Spearman's  $r=-0.773$ ,  $p=0.009$ , online supplementary figure S1).

### Meta-analysis of childhood-onset LHON

Our systematic review of the literature identified 69 patients with LHON with onset of vision loss at the age of 12 years or

**Table 1** Demographics and clinical features of patients included in the UK paediatric LHON cohort

Patient	Mutation	Family history	f/m	Age at onset (years)	Mode of onset	Disease progression	Final BCVA*		Time from onset (years)
							RE	LE	
1	11778	Yes	f	6	S	Gradual visual deterioration over 2 years.	0.17	0.02	47
2	11778	Yes	f	8	A	No recovery.	LP	LP	56
3	11778	Yes	f	9	A	No recovery.	0.03	0.03	38
4	11778	Yes	m	11	A	Worst BCVA: HM BE. Recovery within 12 months from onset.	0.76	0.50	1
5	11778	No	m	8	A	No recovery.	CF	CF	33
6	11778	No	m	3	I	Subnormal vision since birth.	0.17	0.50	52
7	11778	No	m	9	A	Worst BCVA: 0.08 RE, 0.4 LE. Asymmetrical.	0.10	0.50	18
8	11778	Yes	m	11	A	No recovery.	0.07	0.10	2
9	11778	No	m	2	I	Subnormal vision detected when 2 years old. LHON diagnosed at the age of 8 years.	0.25	0.08	17
10	11778	Yes	m	8	A	No recovery.	CF	CF	10
11	11778	No	m	10	A	Worst BCVA: CF BE. Recovery within 24 months from onset. Asymmetrical recovery.	0.08	0.66	7
12	11778	Yes	m	2	I	Subnormal vision detected when 2 years old. LHON diagnosed at the age of 6 years with BCVA of 0.18 RE and 0.17 LE. Slow visual recovery until 10 years old.	0.35	0.36	4
13	11778	Yes	m	2	I	Optic atrophy noted at the age of 2 years. LHON diagnosed at the age of 17 years.	0.40	0.10	15
14	3460	Yes	f	7	A	Worst BCVA: 0.05 BE. Recovery within 4 years from onset.	0.79	0.79	4.5
15	3460	No	f	11	A	No recovery.	CF	CF	10
16	3460	Yes	m	4	I	Poor visual acuity noticed at preschool screening assessment.	0.17	0.17	16
17	3460	No	m	6	A	Asymmetrical visual recovery.	0.67	0.25	18
18	3460	Yes	m	8	A	Worst BCVA: 0.05 BE. Recovery within 12 months from onset.	1.20	1.20	1
19	3460	Yes	m	10	A	Worst BCVA: HM RE, CF LE. Recovery.	0.33	0.50	1.5
20	3460	No	m	5	A	Worst BCVA: 0.1 BE. Recovery within 24 months from onset.	1.00	1.00	2
21	14484	Yes	f	9	S	Gradual visual deterioration over 2 years.	0.17	0.25	29
22	14484	Yes	m	10	A	Recovery within 9 months from onset.	1.00	1.00	16
23	14484	Yes	m	5	I	Poor visual acuity noticed at preschool screening assessment.	0.25	0.25	39
24†	14484	Yes	f	6	A	Worst BCVA: 0.02 RE, 0.2 LE. Recovery within 5 years from onset.	0.91	1.00	18
25†	14484	Yes	m	6	S	Asymmetrical visual recovery.	0.69	0.14	13
26†	14484	Yes	m	4	S	Slowly progressive visual deterioration in the LE only.	1.00	0.10	13
27†	14484	Yes	m	5	A	Off-chart vision (BE) at the nadir. Asymmetrical recovery within 2–3 years from onset.	0.07	0.67	28

\*BCVA recorded at last follow-up clinic visit in Snellen decimal.

†From the same pedigree.

A, acute; BCVA, best corrected visual acuity; BE, both eyes; CF, counting fingers at 0.25 metre; f, female; HM, hand movement; I, insidious; LE, left eye; LP, light perception; m, male; RE, right eye; S, slowly progressive.

**Table 2** Data summary of patients included in the UK paediatric LHON cohort

Mutation	Patients (pedigrees) n	Sex			Age at onset (years) Mean, Median	Acute onset n (%)	Slowly progressive onset n (%)	Insidious/subclinical onset n (%)	Visual recovery* n (%)	BCVA Mean, Median	BCVA $\geq 0.5$ n (%)	BCVA $< 0.05$ n (%)
		f	m	m:f								
11778	13 (13)	3	10	3.3	6.8, 8.0	8 (61)	1 (7)	4 (30)	6 (23)	0.20, 0.10	5/26 (19)	9/26 (35)
3460	7 (7)	2	5	2.5	7.3, 7.0	6 (86)	0	1 (14)	8 (57)	0.60, 0.73	8/14 (57)	2/14 (14)
14484	7 (4)	2	5	2.5	6.4, 6.0	3 (29)	3 (29)	1 (14)	6 (43)	0.54, 0.46	7/14 (50)	0/14 (0)
All	27 (24)	7	21	3.0	6.9, 7.0	17/27 (63)	4/27 (15)	6/27 (22)	20/54 (37)	0.39, 0.25	20/54 (37)	11/54 (20)


\*Number of eyes with visual recovery.

†Number of eyes with BCVA  $\geq 0.5$  or  $< 0.05$  in Snellen decimal.

BCVA, best corrected visual acuity; f, female; LHON, Leber hereditary optic neuropathy; m, male.

younger (mean=8.5 years, median=8.0 years, range=3–12 years) from 20 original publications covering diverse populations: Australia, Brazil, Chile, China, Finland, France, Germany, Italy, Saudi Arabia, Switzerland, the UK and USA (see online supplementary table S1 and online supplementary appendix). The m.11778G>A mutation accounted for 47/69 (69%) of all

the included cases. Visual acuity data were available for 40 patients and overall, 18/79 (23%) eyes achieved a BCVA  $\geq 0.5$  whereas 18/79 (23%) eyes achieved a BCVA  $< 0.05$ . We merged the UK paediatric and historical LHON cohorts to generate a meta-analysis of childhood-onset LHON (see online supplementary table S2 and figure S2). The number of patients



**Figure 1** Distribution of best-corrected visual acuity (BCVA) in the UK paediatric Leber hereditary optic neuropathy (LHON) cohort stratified according to the genotype. Off-chart refers to the number of eyes with BCVA worse than 0.05.

with a BCVA  $\geq 0.5$  in at least one eye was 26/67 (39%) whereas the number of patients with a BCVA  $< 0.05$  in their better seeing eye was 13/67 (19%).

## DISCUSSION


LHON is a disease of young adults and due to its relative rarity, there are limited data on the clinical features and visual prognosis of childhood LHON. In this study, we first identified a UK paediatric LHON cohort consisting of 27 patients diagnosed before the age of 12 years, which was then combined with a historical cohort of 69 eligible patients from 20 previously published reports (see online supplementary appendix). These two cohorts had similar clinical and molecular genetic profiles and we therefore combined the data to generate a meta-analysis for a more comprehensive comparison with classical adult-onset LHON.

The distribution of the three major disease-causing LHON mutations (m.3460G>A=19%, m.11778G>A=62.5% and m.14484T>C=19%) in the childhood cohort is comparable with previously reported adult LHON case series with the m.11778G>A mtDNA mutation being the most common genotype. As expected, there was a male preponderance, but the overall male:female ratio of 1.8 is less marked than the fourfold

to fivefold increased risk of visual loss seen among adult male carriers.<sup>13 14</sup> The mechanisms contributing to this rather intriguing male bias are not fully understood and a number of secondary genetic, hormonal and environmental risk factors have been implicated.<sup>15</sup> Smoking and to a lesser extent heavy drinking are regarded as important environmental triggers, but these factors are unlikely to be aetiologically important in young children. Although this hypothesis needs to be formally verified, the less pronounced sex bias in childhood LHON could arise because it is more heavily genetically determined by nuclear modifiers, which contribute to an earlier age of onset, but that are less sex determined or influenced. The other phenotypical extreme would be late-onset adult cases over the age of 50 years where environmental risk factors, in particular smoking, are thought to play a more prominent role in precipitating disease conversion.<sup>16 17</sup> A systematic genomic comparison of childhood LHON, classical acute cases in young adults and late-onset LHON could therefore prove the key to dissecting the complex genetic-environmental modulators that contribute to visual loss in different groups of susceptible carriers.

The classical acute pattern of vision loss was the most common presentation in childhood LHON, but over a third of patients either had a slowly progressive onset or even more strikingly, a subclinical or insidious disease evolution. In a previous report of 14 children with LHON from Barboni and colleagues, the 6 patients classified as having a slowly progressive course achieved better final visual acuities compared with the acute group.<sup>7</sup> In contrast with this finding, the four patients in the UK paediatric LHON cohort did not have a better prognosis, with the vision deteriorating in the majority of eyes to less than the driving standards, that is, BCVA  $< 0.5$ . The insidious/subclinical LHON subgroup was observed with all three major disease-causing mtDNA mutations and the defining observation was the significant delays in reaching a confirmed molecular diagnosis, which ranged from 3 years to 15 years. Visually asymptomatic children in whom subnormal vision and optic atrophy, which can be subtle, are detected incidentally have been reported previously and the diagnostic challenges are likely to be multifactorial.<sup>10 18</sup> Visual performance in this age group is not always impaired due to the inherent adaptive capacity of young children and importantly, they may not be able to communicate changes in their vision effectively to their parents or guardians. A lack of clinical awareness of LHON in young children is also likely to be relevant in explaining the diagnostic delays in this patient group.

LHON has a major impact on quality of life and the majority of patients will remain within the criteria for legal blindness.<sup>19</sup> The observed overall rates of spontaneous visual recovery of 37% for all eyes in the entire UK paediatric LHON cohort and of 59% for the eyes of patients with acute LHON, are in line with the corresponding values of 28% and 63% reported by Barboni and colleagues.<sup>7</sup> Patients with adult-onset LHON harbouring the m.14484T>C mutation have the best visual prognosis with a partial visual recovery rate of 37%–58% compared with 4%–25% for the m.11778G>A mutation and 22%–25% for the m.3460G>A mutation.<sup>6 8 20–22</sup> The variations in the reported rates of spontaneous visual recovery reflect possible sampling bias depending on the cohort size and the different criteria used to define a visually significant change in visual acuity from the nadir.<sup>3</sup> In our study, the rates of spontaneous visual recovery were 57%, 23% and 43% for the m.3460G>A, m.11778G>A and m.14484T>C mutations, respectively. Children carrying the m.3460G>A mutation therefore seem to have a better visual prognosis, and the recovery rate observed



**Figure 2** Distribution of best-corrected visual acuity (BCVA) in the UK paediatric Leber hereditary optic neuropathy (LHON) cohort stratified according to the pattern of visual loss at disease onset. Off-chart refers to the number of eyes with BCVA worse than 0.05.



with the m.11778G>A mutation is also higher, compared with the clinical impression in patients with adult-onset LHON.<sup>6 21</sup> Based on our meta-analysis of 67 patients for whom visual acuity data were available, 39% of patients achieved a BCVA  $\geq 0.5$  in at least one eye whereas 19% of patients had a BCVA  $< 0.05$  in their better seeing eye. A more favourable final visual outcome was observed for all three genotypes in our childhood-onset LHON cohort compared with previously published figures (m.3460G>A: 14% vs 55%–96%; m.11778G>A: 45% vs 73%–98%; and m.14484T>C mutation: 6% vs 30%–50% of eyes achieving a BCVA  $< 0.1$ ).<sup>1 6 8 20 21</sup> Mitochondrial turnover is implicated in the pathogenesis of LHON, both mitochondrial biogenesis and mitophagy being increased in fibroblasts of patients with LHON.<sup>23 24</sup> The known age-related decline in mitophagy, and hence presumably mitochondrial biogenesis, may underlie this difference from adult disease.<sup>25</sup>

In conclusion, childhood-onset LHON represents a distinct phenotypical subgroup characterised by a more varied clinical evolution and a more favourable visual prognosis compared with classical adult LHON. Importantly, children do not always develop acute or subacute visual symptoms and a high index of suspicion is required in children presenting with unexplained subnormal vision and optic disc pallor to avoid potentially long diagnostic delays.

#### Author affiliations

<sup>1</sup>UCL Institute of Ophthalmology, London, UK

<sup>2</sup>Moorfields Eye Hospital, London, UK

<sup>3</sup>Department of Ophthalmology, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland

<sup>4</sup>Great Ormond Street Hospital, London, UK

<sup>5</sup>Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK

<sup>6</sup>Department of Ophthalmology, Royal United Hospital, Bath, UK

<sup>7</sup>Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

<sup>8</sup>Medical Research Council Mitochondrial Biology Unit, Cambridge, UK

<sup>9</sup>Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge, UK

<sup>10</sup>School of Optometry and Vision Sciences, Cardiff University and Cardiff Eye Unit, University Hospital Wales, Cardiff, UK

<sup>11</sup>Ophthalmology Department, UCSF School of Medicine, San Francisco, California, USA

<sup>12</sup>Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK

**Contributors** Research design: AM, MV, ATM, PY-W-M. Data acquisition and/or research execution: AM, RB, JP, RJA, MAR, MM, ARW, MV, ATM, PY-W-M. Data analysis and/or interpretation: AM, PFC, MV, ATM, PY-W-M. Manuscript preparation: AM, PY-W-M.

**Funding** This research was supported by the National Institute for Health Research Rare Diseases Translational Research Collaboration (NIHR RD-TRC) and the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology, the NIHR Moorfields Clinical Research Facility. AM receives funding from Suomen Silmätutkimusseura ry:n Apurahasäätiö (Finland). MV and PY-W-M receive funding from Fight for Sight (UK). ATM, MV, PFC and PY-W-M receive funding from the UK National Institute of Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration. PY-W-M is supported by a Clinician Scientist Fellowship Award (G1002570) from the Medical Research Council (UK). PFC is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC\_UP\_1501/2), the Wellcome Trust Centre for Mitochondrial Research (096919Z/11/Z), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943). JP was funded by the MRC (MR/J010448/1) and the Wellcome Trust (0948685/Z/10/Z) and has salary support from the NHS specialised Services Rare Mitochondrial Disorders Service.

**Competing interests** PY-W-M holds a consultancy agreement with GenSight Biologics (Paris, France).

**Ethics approval** The ethics committee at Moorfields Eye Hospital, London, UK.

**Provenance and peer review** Not commissioned; externally peer reviewed.

#### REFERENCES

- 1 Nikoskelainen EK, Huoponen K, Juvonen V, *et al*. Ophthalmologic findings in Leber Hereditary Optic Neuropathy, with special reference to mtDNA mutations. *Ophthalmology* 1996;103:504–14.
- 2 Yu-Wai-Man P, Chinnery PF. Leber Hereditary Optic Neuropathy. In: Pagon RA, Adam MP, Ardinger HH, *et al*. eds. *GeneReviews*® [Internet]. Seattle, WA: University of Washington, Seattle, 1993–2016. 2000 Oct 26 (updated 2013 Sep 19).
- 3 Yu-Wai-Man P, Votruba M, Moore AT, *et al*. Treatment strategies for inherited optic neuropathies—past, present and future. *Eye (Lond)* 2014;28:521–37.
- 4 Mackey DA, Oostra RJ, Rosenberg T, *et al*. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. *Am J Hum Genet* 1996;59:481–5.
- 5 Bosley TM, Brodsky MC, Glasier CM, *et al*. Sporadic bilateral optic neuropathy in children: the role of mitochondrial abnormalities. *Invest Ophthalmol Vis Sci* 2008;49:5250–6.
- 6 Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. *Am J Ophthalmol* 1991;111:750–62.
- 7 Barboni P, Savini G, Valentino ML, *et al*. Leber's hereditary optic neuropathy with childhood onset. *Invest Ophthalmol Vis Sci* 2006;47:5303–9.
- 8 Johns DR, Smith KH, Miller NR. Leber's hereditary optic neuropathy: clinical manifestations of the 3460 mutation. *Arch Ophthalmol* 1992;110:1577–81.
- 9 Mackey D, Howell N. A variant of Leber hereditary optic neuropathy characterized by recovery of vision and by an unusual mitochondrial genetic etiology. *Am J Hum Genet* 1992;51:1218–28.
- 10 Pezzi PP, De Negri AM, Sadun F, *et al*. Childhood Leber's hereditary optic neuropathy (ND1/3460) with visual recovery. *Pediatr Neurol* 1998;19:308–12.
- 11 Majander A, Bitner-Glindzicz M, Chan CM, *et al*. Lamination of the outer plexiform layer in optic atrophy caused by dominant *WFS1* mutations. *Ophthalmology* 2016;123:1624–6.
- 12 Yu-Wai-Man P, Bailie M, Atawan A, *et al*. Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. *Eye (Lond)* 2011;25:596–602.
- 13 Puomila A, Hämmäläinen P, Kivioja S, *et al*. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. *Eur J Hum Gen* 2007;15:1079–89.
- 14 Black GC, Craig IW, Oostra RJ, *et al*. Leber's hereditary optic neuropathy: implications of the sex ratio for linkage studies in families with the 3460 ND1 mutation. *Eye (Lond)* 1995;9(Pt 4):513–16.
- 15 Kirkman MA, Yu-Wai-Man P, Korsten A, *et al*. Gene-environment interactions in Leber hereditary optic neuropathy. *Brain* 2009;132:2317–26.
- 16 Carelli V, d'Adamo P, Valentino ML, *et al*. Parsing the differences in affected with LHON: genetic versus environmental triggers of disease conversion. *Brain* 2016;139(Pt 3):e17.
- 17 Yu-Wai-Man P, Hudson G, Klopstock T, *et al*. Reply: parsing the differences in affected with LHON: genetic versus environmental triggers of disease conversion. *Brain* 2016;139(Pt 3):e18.
- 18 Moorman CM, Elston JS, Matthews P. Leber's hereditary optic neuropathy as a cause of severe visual loss in childhood. *Pediatrics* 1993;91:988–9.
- 19 Kirkman MA, Korsten A, Leonhardt M, *et al*. Quality of life in patients with Leber hereditary optic neuropathy. *Invest Ophthalmol Vis Sci* 2009;50:3112–15.
- 20 Johns DR, Heher KL, Miller NR, *et al*. Leber's hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. *Arch Ophthalmol* 1993;111:495–8.
- 21 Riordan-Eva P, Sanders MD, Govan GG, *et al*. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. *Brain* 1995;118(Pt 2):319–37.
- 22 Lam BL, Feuer WJ, Schiffman JC, *et al*. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial. *JAMA Ophthalmol* 2014;132:428–36.
- 23 Giordano C, Iommarini L, Giordano L, *et al*. Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy. *Brain* 2014;137:335–53.
- 24 Dombl E, Diot A, Morten K, *et al*. The m.13051G>A mitochondrial DNA mutation results in variable neurology and activated mitophagy. *Neurology* 2016;86:1921–3.
- 25 Diot A, Hinks-Roberts A, Lodge T, *et al*. A novel quantitative assay of mitophagy: combining high content fluorescence microscopy and mitochondrial DNA load to quantify mitophagy and identify novel pharmacological tools against pathogenic heteroplasmic mtDNA. *Pharmacol Res* 2015;100:24–35.



## Childhood-onset Leber hereditary optic neuropathy

Anna Majander, Richard Bowman, Joanna Poulton, Richard J Antcliff, M Ashwin Reddy, Michel Michaelides, Andrew R Webster, Patrick F Chinnery, Marcela Votruba, Anthony T Moore and Patrick Yu-Wai-Man

*Br J Ophthalmol* 2017 101: 1505-1509 originally published online March 17, 2017

doi: 10.1136/bjophthalmol-2016-310072

---

Updated information and services can be found at:  
<http://bjo.bmj.com/content/101/11/1505>

---

*These include:*

### References

This article cites 24 articles, 4 of which you can access for free at:  
<http://bjo.bmj.com/content/101/11/1505#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections

[Open access](#) (273)

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>